Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-004450-21-IT (EUCTR)	07/02/2014	12/12/2013	study to evaluate whether the administration of Rebif ® 44 three times a week in the morning can reduce the severity of flu-like symptoms compared to administration in the evening, in patients with relapsing multiple sclerosis not yet treated.	Multicenter, open-label, 12 weeks,phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a(Rebif®) administered In the morning may affEct the severity of Flu-like syndromeand patient perceived invisible symptoms in subjects with relapsing multiple sclerosis - RELIEF	relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia Product Name: Rebif ®	Merck Serono S.p.A.	NULL	Not Recruiting			Female: yes Male: yes	218	Phase 4	Italy